We quantified HER2 expression in various human pancreatic cancer cell lines and studied the bioactivity of this antibody both in vitro and in vivo. Growth inhibition by Herceptin was observed in vitro in cell lines with high levels of HER2/neu expression. Cell lines with low levels of this ...
T-DXd is an antibody drug conjugate targeting HER2 and is approved in HER2-expressing breast (BC) and gastric (GC) cancers. HER2 expression is prevalent in other solid tumors. The efficacy of current treatments (Tx) in th...
“In gastric [cancer] we’re starting to see [activity with T-DXd] in the intermediate [HER2] expressors, [although] it’s not as striking as the breast data,” Parikh said. “Unfortunately, pancreatic cancer is the notable disease [with a] lack of efficacy, but across other GI ...
The effectiveness of T-DXd in breast cancer patients with low expression of HER2 expression (IHC1+ or IHC2+ and FISH-) was confirmed by the randomized controlled phase III study, DESTINY-Breast04 [65]. This finding provides a novel justification for the precise treatment of patients exhibiting...
HER2 or ErbB2 is a member of the epidermal growth factor family and is a well-established biomarker that is overexpressed in a wide variety of tumor types including breast, ovarian, gastric, colorectal, pancreatic, and endometrial cancers. HER2 regulates
[7] Seo AN, Kwak Y, Kim DW, et al. HER2 status in colorectal cancer: its clinical significance and the relationship between HER2 gene amplification and expression[J]. PLoS One, 2014, 9(5): e98528. DOI:10.1371/journal.pone.0098528 ...
Thrombin treatment was used to isolate plasma EVs collected from 3 groups of subjects: (1) HER2 group: four breast cancer patients with elevated HER2 protein expression (two patients were HER2-positive with IHC 3+; one patient was HER2-positive with IHC 1+, and one patient was HER2-low wit...
A living biobank of breast cancer organoids captures disease heterogeneity. Cell 172, 373–386 (2018). CAS PubMed Google Scholar Grunwald, B. T. et al. Spatially confined sub-tumor microenvironments in pancreatic cancer. Cell 184, 5577–5592 (2021). CAS PubMed Google Scholar Hao, Y. ...
(n = 366) given on day 1 every 3 weeks, both with CAPOX chemotherapy (1000 mg/m2of oral capecitabine taken twice a day on days 1 to 14 every 3 weeks and 130 mg/m2of intravenous oxaliplatin given on day 1 every 3 weeks). Randomization was stratified by PD-L1 expression status, ECOG...
The DESTINY-Breast04 trial has recently demonstrated survival benefits of trastuzumab-deruxtecan (T-DXd) in metastatic breast cancer patients with low Human Epidermal Growth Factor Receptor 2 (HER2) expression. Accurate differentiation of HER2 scores has now become crucial. However, visual immunohistoche...